Kiltearn Partners LLP Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Kiltearn Partners LLP lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 107.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,900 shares of the biopharmaceutical company’s stock after purchasing an additional 78,300 shares during the quarter. Gilead Sciences accounts for about 2.3% of Kiltearn Partners LLP’s investment portfolio, making the stock its 20th biggest holding. Kiltearn Partners LLP’s holdings in Gilead Sciences were worth $13,939,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new stake in Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences in the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Up 1.7 %

Shares of NASDAQ GILD opened at $111.16 on Friday. The business’s 50 day moving average price is $105.08 and its 200-day moving average price is $94.58. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $138.43 billion, a price-to-earnings ratio of 300.43, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.84%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. Piper Sandler upped their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Morgan Stanley boosted their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $105.12.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.